Similarly, effector Th1 responses, such as increased IFNγ production, concurrently lead to increased expression of PD-L1 on multiple cell types, including tumor cells and macrophages, which can engage the PD-1 receptor on T cells to suppress anti-tumor immunity [116,117]. The gene discussed is CD274; the disease is neoplasm.